Texas Attorney General Ken Paxton claims the makers of Tylenol failed to warn consumers of the risks. Here's who makes Tylenol and its ties to NJ.

Kenvue (NYSE:KVUE), the consumer healthcare spin-off from Johnson & Johnson, has experienced a significant decline in its stock price in recent months.

Canaccord said the headlines are likely to distract management and stall Kenvue’s operational turnaround, which had shown early progress earlier this year. The firm noted that Kenvue’s skin health and beauty segment, particularly Neutrogena, was improving, and cost savings followed its separation from Johnson & Johnson in 2023.

The makers of Tylenol, Johnson & Johnson and Kenvue, were sued on Tuesday by Texas Attorney General Ken Paxton, who accused them of knowingly hiding the drug's links to autism and attention deficit hyperactivity disorder.

A potential legal headache for consumer healthcare giant Kenvue ( KVUE 8.36%) was causing pain for investors on Thursday. Such troubles tend to spook the market; hence the more than 13% sell-off of Kenvue across that trading session. The S&P 500 ( ^GSPC 0.53%), by comparison, did much better on the day with "only" a 0.6% decrease.

Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2025 financial results before the market opens on November 6, 2025.

Kenvue urged U.S. regulators to deny a request warning against Tylenol’s use during pregnancy, laying out the most detailed defense of its biggest product after Trump administration officials tied its use to autism.